Scancell cancer news
Scancell unveiled its Moditope vaccine technology that stimulates the production of killer CD4 T cells against cancer. The company said its board is evaluating strategic options for the technology. Scancell added that the Moditope epitopes can be used to develop DNA and peptide vaccines. The company also reiterated its strategy to seek a buyer for its DNA ImmunoBody vaccine technology and its lead ImmunoBody, SCIB1, after completion of a Phase I/II trial in melanoma, which is expected late next year. SCIB1 is a cancer vaccine comprising the melanoma antigen tyrosinase-related protein 2 (TRP2) and two helper T cell epitopes. SCIB1 is delivered using the TriGrid electroporation delivery device from Ichor Medical Systems Inc. (San Diego, Calif.). Scancell's SCIB2, an ImmunoBody cancer vaccine that stimulates immune responses to the lung cancer antigen cancer/testis antigen 1B ( CTAG1B; NY-ESO-1), is in preclinical development. ...